Skip to main content
Premium Trial:

Request an Annual Quote

MDS Sciex to Move Beyond Mass Spec with Upcoming Cell Analysis Platform

BOSTON, Aug. 12 (GenomeWeb News) - MDS Sciex is diversifying its product offerings beyond its flagship line of mass spectrometry instruments to include cellular analysis, the company said at IBC's Drug Discovery Technology conference, held here this week.

 

MDS Sciex, the analytical instruments division of publicly traded biotech firm MDS, was previewing its newest product, CellKey, at the meeting. A company official told GenomeWeb News' sister publication Cell-Based Assay News that it plans to officially launch the product next month at the Society for Biomolecular Screening conference in Geneva.

 

CellKey is a label-free cellular analysis platform based on cellular dielectric spectroscopy. In this technique, cells are grown on electrodes embedded in microwell plates, and a constant low-level voltage is applied. A detection instrument senses changes in electrical impedance that result from changes in cell morphology, confluence, adherence, and interactions.

 

For further details about the product, MDS Sciex' commercialization plans, and the competitive landscape for this technology, see the Aug. 15 issue of Cell-Based Assay News.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.